Fu-Shun Yen1, Jen-Huai Chiang2, Chun-Wei Pan3, Boniface J Lin4, James Cheng-Chung Wei5, Chih-Cheng Hsu6. 1. Dr. Yen's Clinic, No. 15, Shanying Rd., Gueishan Dist., Taoyuan City 33354, Taiwan. Electronic address: yenfushun@gmail.com. 2. Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan; College of Medicine, China Medical University, Taichung, Taiwan. Electronic address: zinvii@gmail.com. 3. University of the East Ramon Magsaysay Medical Center Inc, 64 Aurora Boulevard, Barangay Doña Imelda, Quezon City 1113, Philippines. Electronic address: wpan931109@gmail.com. 4. Lin Clinic, No. 2, Sec. 2, Xinsheng S. Rd., Da'an Dist., Taipei City 10650, Taiwan. Electronic address: boniface.lin@gmail.com. 5. Institute of Medicine, Chung Shan Medical University, Department of Medicine, Chung Shan Medical University Hospital, Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. Electronic address: jccwei@gmail.com. 6. Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan; Department of Family Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan; Department of Health Services Administration, China Medical University, Taichung, Taiwan. Electronic address: cch@nhri.org.tw.
Abstract
AIMS: To compare the hazard of cardiovascular diseases between DPP-4 inhibitor users and non-users who were on insulin therapy. METHODS: We conducted a population-based cohort study. 2652 patients with type 2 diabetes mellitus (T2DM) under insulin therapy were enrolled during 1997-2010. The incidence rates per 1000 person-years (PYs) of stroke, coronary heart disease (CAD) and heart failure were compared between 1326 DPP-4 inhibitor users and 1326 propensity score matched non-users. Multivariable Cox proportional hazards model was used to evaluate excess risk of the DPP-4 inhibitor non-users. RESULTS: After adjustment of age, gender, comorbidities, drugs used and diabetes duration; the incidence rate per 1000 PYs were 21.70 and 9.88 in DPP-4 inhibitor non-users and users; DPP-4 inhibitor users had lower hazard ratio (HR) of stroke (adjusted HR: 0.59, 95% CI: 0.42-0.83, p value: 0.002) compared with non-users. The incidence rates per 1000 PYs of CAD and heart failure of control versus users were 19.85 versus 13.54 and 5.56 versus 4.78; the adjusted HRs of CAD and heart failure were 0.86 and 1.11. Both were non-significant. CONCLUSION: This nationwide study demonstrated that insulin plus DPP-4 inhibitor users had significantly lower risk of stroke as compared with non-users.
AIMS: To compare the hazard of cardiovascular diseases between DPP-4 inhibitor users and non-users who were on insulin therapy. METHODS: We conducted a population-based cohort study. 2652 patients with type 2 diabetes mellitus (T2DM) under insulin therapy were enrolled during 1997-2010. The incidence rates per 1000 person-years (PYs) of stroke, coronary heart disease (CAD) and heart failure were compared between 1326 DPP-4 inhibitor users and 1326 propensity score matched non-users. Multivariable Cox proportional hazards model was used to evaluate excess risk of the DPP-4 inhibitor non-users. RESULTS: After adjustment of age, gender, comorbidities, drugs used and diabetes duration; the incidence rate per 1000 PYs were 21.70 and 9.88 in DPP-4 inhibitor non-users and users; DPP-4 inhibitor users had lower hazard ratio (HR) of stroke (adjusted HR: 0.59, 95% CI: 0.42-0.83, p value: 0.002) compared with non-users. The incidence rates per 1000 PYs of CAD and heart failure of control versus users were 19.85 versus 13.54 and 5.56 versus 4.78; the adjusted HRs of CAD and heart failure were 0.86 and 1.11. Both were non-significant. CONCLUSION: This nationwide study demonstrated that insulin plus DPP-4 inhibitor users had significantly lower risk of stroke as compared with non-users.
Authors: Ioannis Akoumianakis; Ileana Badi; Gillian Douglas; Surawee Chuaiphichai; Laura Herdman; Nadia Akawi; Marios Margaritis; Alexios S Antonopoulos; Evangelos K Oikonomou; Costas Psarros; Nikolaos Galiatsatos; Dimitris Tousoulis; Attila Kardos; Rana Sayeed; George Krasopoulos; Mario Petrou; Uwe Schwahn; Paulus Wohlfart; Norbert Tennagels; Keith M Channon; Charalambos Antoniades Journal: Sci Transl Med Date: 2020-04-29 Impact factor: 17.956
Authors: David Diaz-Jimenez; Maria Grazia Petrillo; Jonathan T Busada; Marcela A Hermoso; John A Cidlowski Journal: J Biol Chem Date: 2020-01-27 Impact factor: 5.157